106,951 Shares in 908 Devices Inc. $MASS Acquired by Nuveen LLC

Nuveen LLC purchased a new stake in 908 Devices Inc. (NASDAQ:MASS) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 106,951 shares of the company’s stock, valued at approximately $479,000. Nuveen LLC owned 0.30% of 908 Devices as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Invesco Ltd. bought a new stake in shares of 908 Devices in the 1st quarter valued at $2,910,000. Charles Schwab Investment Management Inc. boosted its stake in shares of 908 Devices by 5.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 212,230 shares of the company’s stock valued at $951,000 after purchasing an additional 10,462 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of 908 Devices by 115.6% in the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 22,862 shares of the company’s stock valued at $102,000 after purchasing an additional 12,258 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of 908 Devices in the 1st quarter valued at $2,153,000. Finally, ARK Investment Management LLC boosted its stake in shares of 908 Devices by 4.0% in the 1st quarter. ARK Investment Management LLC now owns 2,899,347 shares of the company’s stock valued at $12,989,000 after purchasing an additional 110,781 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at 908 Devices

In related news, insider Michael S. Turner sold 7,148 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $7.51, for a total value of $53,681.48. Following the completion of the sale, the insider directly owned 1,373 shares of the company’s stock, valued at approximately $10,311.23. This represents a 83.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 24,603 shares of company stock valued at $184,755. Corporate insiders own 23.70% of the company’s stock.

908 Devices Price Performance

Shares of 908 Devices stock opened at $5.50 on Friday. The stock has a market cap of $197.23 million, a price-to-earnings ratio of -10.19 and a beta of 0.37. The firm’s 50-day moving average is $6.59 and its 200 day moving average is $5.44. 908 Devices Inc. has a 1 year low of $1.81 and a 1 year high of $8.06.

908 Devices (NASDAQ:MASS) last posted its earnings results on Tuesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). 908 Devices had a negative net margin of 30.54% and a negative return on equity of 24.30%. The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $12.17 million. 908 Devices has set its FY 2025 guidance at EPS. On average, equities analysts expect that 908 Devices Inc. will post -1.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MASS. Leerink Partners raised shares of 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 target price on the stock in a research note on Tuesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a report on Saturday, August 30th. Leerink Partnrs upgraded shares of 908 Devices from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 5th. Finally, Wall Street Zen upgraded shares of 908 Devices from a “sell” rating to a “hold” rating in a research report on Saturday, August 30th. One analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $8.00.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.